Suggestions
Gabriela Andrejeva
Principal Scientist, Oncology at Recursion
Professional Background
Gabriela Andrejeva is an accomplished biotherapeutics professional with a rich tapestry of experience spanning over seven years post-PhD, primarily focusing on the dynamic fields of immuno-oncology, as well as inflammatory and autoimmune diseases. Her journey traverses both academic research and industry applications, showcasing her versatility and depth in pharmaceuticals. Most notably, Gabriela is currently serving as the Principal Scientist for Oncology at Recursion, where she harnesses her knowledge to innovate and advance therapeutic strategies using cutting-edge technology.
In her previous role as Lead for In Vivo studies at Arch Oncology, Gabriela led a team dedicated to developing innovative treatments targeting complex cancers, bringing her expertise in antibody therapeutics and in vitro immunological screens to the forefront of cancer research. As a Senior Scientist and Research Scientist at Arch Oncology, she contributed to multiple projects aiming to identify and develop potent cancer therapies, leveraging her extensive background in preclinical murine oncology models to assess both efficacy and safety outcomes effectively.
Gabriela's experience also extends to her role as a Postdoctoral Research Fellow at Vanderbilt University, where she deepened her understanding of the immune system's interaction with cancer and its potential for therapeutic intervention. Her academic journey began at The Institute of Cancer Research, U. of London, where she not only completed her PhD but also contributed valuable research findings aimed at establishing druggable metabolic targets in T cells for various diseases as well as gaining insight into autophagy-induced drug resistance in cancer cells.
Education and Achievements
Gabriela's educational background is as impressive as her professional experience. She holds a Doctor of Philosophy (PhD) in Oncology and Cancer Biology from The Institute of Cancer Research, U. of London, which is recognized globally as a premier institution devoted to cancer research. During her time there, she conducted groundbreaking research that has been influential in understanding the underlying mechanisms of cancer biology and treatment resistance.
Her academic pursuits were enriched by her participation in the ERASMUS program at the University of Groningen. This opportunity not only broadened her educational experience but also allowed her to engage with diverse ideas and research methodologies in Europe. Gabriela completed her Master of Biochemistry at the prestigious University of Oxford, where her foundation in biochemistry was solidified, equipping her with essential knowledge and skills that are vital in the biotherapeutics domain.
Throughout her career, Gabriela has made significant contributions to the scientific community. Her work has led to 13 peer-reviewed publications and 2 patent applications, reflecting her ability to not only innovate but also contribute to the advancement of research knowledge within her fields of expertise. These publications are a testament to her dedication to scientific inquiry and her commitment to sharing her findings with the global research community.
Achievements
Gabriela Andrejeva's achievements in the field of biotherapeutics are commendable and demonstrate her relentless pursuit of excellence. Over her years of experience, she has successfully transformed academic research into practical applications, thus contributing to the development of novel cancer therapies that have the potential to significantly improve patient outcomes.
She has become a recognized figure in the scientific community, contributing to a variety of research efforts that intersect immunology and oncology, making her a valuable collaborator and thought leader in her roles. Gabriela exhibits strong organizational and record-keeping skills, which are crucial for driving projects forward, particularly in fast-paced environments like cancer research, where precision and accountability are paramount.
Her collaborative nature allows her to thrive in team settings, ensuring that projects are executed efficiently and that her scientific peers benefit from her insight. Gabriela's adaptability in dynamic environments has further established her as a reliable figure in the ever-evolving landscape of biotherapeutics. Her ability to navigate complex projects and foster innovation positions her at the forefront of driving future advancements in cancer treatment and therapy development.
